Sanjay Misra1, Ankaj Khosla2, Jake Allred2, William S Harmsen2, Stephen C Textor3, Michael A McKusick4. 1. Vascular and Interventional Radiology Translational Laboratory, Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905. Electronic address: misra.sanjay@mayo.edu. 2. Vascular and Interventional Radiology Translational Laboratory, Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905. 3. Division of Nephrology and Hypertension, Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905. 4. Division of Vascular and Interventional Radiology, Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.
Abstract
PURPOSE: To identify risk factors for progression to renal replacement therapy (RRT) and all-cause mortality in patients who underwent renal artery (RA) stent placement for atherosclerotic renal artery stenosis (RAS). MATERIALS AND METHODS: A retrospective study from June 1996 to June 2009 identified 1,052 patients who underwent RA stent placement. Glomerular filtration rate at time of RA stent placement was estimated from serum creatinine level and divided into chronic kidney disease (CKD) stages 1-5. Univariate and multivariable Cox proportional hazards models were used to determine which factors were associated with each endpoint. RESULTS: Times to progression to all-cause mortality and RRT were similar for CKD stages 1/2/3A and served as the reference group. In multivariable analysis, high-grade proteinuria (P < .001) and higher CKD stage (5 vs 1/2/3A [P < .001], 4 vs 1/2/3A [P < .001], 3B vs 1/2/3A [P = .02]) remained independently associated with increased risk of progression to RRT. Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) use was associated with decreased risk of progression to RRT (P = .03). Higher CKD stage (5 vs 1/2/3A [P < .001], 4 vs 1/2/3A [P = .004]), carotid artery disease (P < .001), diabetes mellitus (P = .002), and high-grade proteinuria (P < .001) remained independently associated with all-cause mortality. Statin use was associated with decreased risk of all-cause mortality (P < .001). CONCLUSIONS: Patients with atherosclerotic RAS who undergo RA stent placement and have high-grade proteinuria and CKD stage 3B/4/5 have increased risk of progression to RRT. Patients with high-grade proteinuria, CKD stage 3B/4/5, carotid artery disease, or diabetes have increased risk for all-cause mortality after renal artery stent placement. Patients receiving ACEI/ARBs have a decreased risk of progression to RRT, and patients receiving statins have a decreased risk of all-cause mortality.
PURPOSE: To identify risk factors for progression to renal replacement therapy (RRT) and all-cause mortality in patients who underwent renal artery (RA) stent placement for atherosclerotic renal artery stenosis (RAS). MATERIALS AND METHODS: A retrospective study from June 1996 to June 2009 identified 1,052 patients who underwent RA stent placement. Glomerular filtration rate at time of RA stent placement was estimated from serum creatinine level and divided into chronic kidney disease (CKD) stages 1-5. Univariate and multivariable Cox proportional hazards models were used to determine which factors were associated with each endpoint. RESULTS: Times to progression to all-cause mortality and RRT were similar for CKD stages 1/2/3A and served as the reference group. In multivariable analysis, high-grade proteinuria (P < .001) and higher CKD stage (5 vs 1/2/3A [P < .001], 4 vs 1/2/3A [P < .001], 3B vs 1/2/3A [P = .02]) remained independently associated with increased risk of progression to RRT. Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) use was associated with decreased risk of progression to RRT (P = .03). Higher CKD stage (5 vs 1/2/3A [P < .001], 4 vs 1/2/3A [P = .004]), carotid artery disease (P < .001), diabetes mellitus (P = .002), and high-grade proteinuria (P < .001) remained independently associated with all-cause mortality. Statin use was associated with decreased risk of all-cause mortality (P < .001). CONCLUSIONS:Patients with atherosclerotic RAS who undergo RA stent placement and have high-grade proteinuria and CKD stage 3B/4/5 have increased risk of progression to RRT. Patients with high-grade proteinuria, CKD stage 3B/4/5, carotid artery disease, or diabetes have increased risk for all-cause mortality after renal artery stent placement. Patients receiving ACEI/ARBs have a decreased risk of progression to RRT, and patients receiving statins have a decreased risk of all-cause mortality.
Authors: R E Zierler; R O Bergelin; R C Davidson; K Cantwell-Gab; N L Polissar; D E Strandness Journal: Am J Hypertens Date: 1996-11 Impact factor: 2.689
Authors: Jose A Silva; Srinivas Potluri; Christopher J White; Tyrone J Collins; J Stephen Jenkins; Rajesh Subramanian; Stephen R Ramee Journal: Catheter Cardiovasc Interv Date: 2007-05-01 Impact factor: 2.692
Authors: J Gregory Modrall; Carlos H Timaran; Eric B Rosero; Jayer Chung; Frank A Arko; R James Valentine; G Patrick Clagett; Clayton Trimmer Journal: J Vasc Surg Date: 2011-07-31 Impact factor: 4.268
Authors: J Radermacher; A Chavan; J Bleck; A Vitzthum; B Stoess; M J Gebel; M Galanski; K M Koch; H Haller Journal: N Engl J Med Date: 2001-02-08 Impact factor: 91.245
Authors: Brenda R Hemmelgarn; Braden J Manns; Anita Lloyd; Matthew T James; Scott Klarenbach; Robert R Quinn; Natasha Wiebe; Marcello Tonelli Journal: JAMA Date: 2010-02-03 Impact factor: 56.272
Authors: Mark G Davies; Wael E Saad; Jean X Bismuth; Joseph J Naoum; Eric K Peden; Alan B Lumsden Journal: J Vasc Surg Date: 2009-02-14 Impact factor: 4.268
Authors: Liesbeth Bax; Arend-Jan J Woittiez; Hans J Kouwenberg; Willem P T M Mali; Erik Buskens; Frederik J A Beek; Branko Braam; Frans T M Huysmans; Leo J Schultze Kool; Matthieu J C M Rutten; Cornelius J Doorenbos; Johannes C N M Aarts; Ton J Rabelink; Pierre-François Plouin; Alain Raynaud; Gert A van Montfrans; Jim A Reekers; Anton H van den Meiracker; Peter M T Pattynama; Peter J G van de Ven; Dammis Vroegindeweij; Abraham A Kroon; Michiel W de Haan; Cornelis T Postma; Jaap J Beutler Journal: Ann Intern Med Date: 2009-05-04 Impact factor: 25.391
Authors: Rafał Badacz; Anna Kabłak-Ziembicka; Agnieszka Rosławiecka; Daniel Rzeźnik; Jakub Baran; Mariusz Trystuła; Jacek Legutko; Tadeusz Przewłocki Journal: J Pers Med Date: 2022-03-28
Authors: Michael C Jundt; Edwin A Takahashi; William S Harmsen; Sanjay Misra Journal: Cardiovasc Intervent Radiol Date: 2019-07-02 Impact factor: 2.740